First Commercial Biosimilar Release in the United States

September 3, 2015

The Wall Street Journal (Grant, 9/3) reported on the release of the first U.S. biosimilar drug. Sandoz announced that it will begin selling Zarxio, its biosimilar of Amgen’s Neupogen. The release is happening after a U.S. appellate court denied Amgen’s request to block its sale. “The initial stakes are low for the imminent launch of the first U.S. biosimilar drug,” although they shouldn’t be expected to stay that way.

Reuters (Hirschler, Shields, 9/3) also reported on the story, noting that Sandoz’ release of Zarxio will be at a 15 percent discount over Amgen’s Neupogen and that “insurers hope biosimilars will eventually cost the public 40 percent to 50 percent less than the original brands.”